Beijing-based Genetron Holdings has received the CE mark for its 8-gene Lung Cancer Assay.

Intended for hospital use, the assay runs on the company’s Genetron S5 sequencing platform and identifies mutations of the EGFR, BRAF, KRAS, HER2 and PIK3CA genes, translocations of ALK and ROS1 genes, and MET exon 14 skipping genes.

The proprietary DNA sequencing method requires just one manual step — mixing reagents with DNA or complementary DNA synthesized from RNA.